Table 3.
Proportion of healthcare-acquired Enterobacteriaceae isolates susceptible to third-generation cephalosporins (and cefepime) in Latin American hospitals.
| Pathogen | SMART 200528 | TEST 2004–200631 | TEST 2004–201032 | SMART 200829 | SMART 2008–200930 | SENTRY 2008–201033 |
|---|---|---|---|---|---|---|
| E. coli | 83–84% (84%a) n = 395 isolates |
82–89% (86%) n = 326 isolates |
82% (94%) n = 2711 non-ESBL isolates |
96% (100%) n > 50 non-ESBL isolates |
94–95% (100%) n = 1043 non-ESBL isolates |
75–82% (84%) n = 1517 isolates |
| 1% (28%) n = 870 ESBL isolates |
2%–28% (7%) n > 50 ESBL isolates |
1%-21% (12%) n = 323 ESBL isolates |
||||
| K. pneumoniae | NR | 53–55% (58%) n = 282 isolates |
77% (88%) n = 1917 non-ESBL isolates |
96–97% (97%) n > 50 non-ESBL isolates |
NR | 47–55% (59%) n = 1052 isolatesb |
| 0% (0%) n = 124 ESBL K. pneumoniae isolates |
1% (29%) n = 1045 ESBL K. pneumoniae isolates |
2%–28% (7%) n > 50 ESBL K. pneumoniae isolates |
||||
| S. marcescens | NR | 77% (82%) n = 124 isolates |
68% (84%) n = 1126 isolates | NR | NR | NR |
NR, not reported; SMART, Study for Monitoring Antimicrobial Resistance Trends; TEST, Tigecycline Evaluation and Surveillance Trial.
a
Throughout table, figures in parentheses are proportions susceptible to cefepime, a fourth-generation cephalosporin.
b
Klebsiella spp.